CSPC Innovation (300765.SZ) announced its first-half results, turning a loss into a profit of 1,261 billion yuan

According to the Zhitong Finance App, Shiyao Innovation (300765.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 3.24 billion yuan, an increase of 208.72% over the previous year. Achieved net profit of 1,261 billion yuan attributable to shareholders of listed companies. Achieve net profit of 1,226 billion yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies. Basic earnings per share were $0.9056.

In the first half of 2026, the company's biopharmaceutical business achieved revenue of 2262.4955 million yuan, an increase of 2319.52% over the previous year. During the reporting period, the company's commercialized biopharmaceutical products continued to deepen in-hospital access and channel coverage, achieving sales revenue of 17.49313 million yuan, an increase of 87.07% over the previous year. The company's usinumab injection (ENYK®) obtained approval for drug production in May and officially entered the commercialization stage in June, and will continue to contribute to product revenue in the future.

During the reporting period, the external licensing (BD) business became the main increase in the company's revenue. In January 2026, Jushi Biotech, a holding subsidiary of the company, signed a “Strategic Cooperation and Authorization Agreement” with AstraZeneca to cooperate with AstraZeneca in the field of innovative peptide drugs. Among them, Jushi Biotech has the right to collect a down payment of US$420 million, and has the right to collect corresponding development milestone payments, sales milestone payments and royalties according to the actual situation of the authorized pipeline. In May 2026, Megalithic has collected the full down payment of US$420,000. In the first quarter of 2026, the company successfully reached the phase II clinical launch milestone of the cooperative project with Corbus, and received a milestone payment of 10 million US dollars in the first half of the year. On July 1, 2026, the company once again signed a global cooperation agreement with AstraZeneca for innovative drugs with small interfering nucleic acid. Jushi Biotech has the right to collect a down payment of 30 million US dollars, and the total subsequent milestones of the project can reach up to 1.74 million US dollars. In August 2026, Megalithic Life collected a full down payment of $30 million.